225 related articles for article (PubMed ID: 17313469)
1. Torsades de pointes associated with voriconazole use.
Philips JA; Marty FM; Stone RM; Koplan BA; Katz JT; Baden LR
Transpl Infect Dis; 2007 Mar; 9(1):33-6. PubMed ID: 17313469
[TBL] [Abstract][Full Text] [Related]
2. OTc prolongation and torsade de pointes ventricular tachycardia in a small dose voriconazole therapy.
Elbey MA; Cil H; Onturk E; Islamoglu Y
Eur Rev Med Pharmacol Sci; 2012 Jan; 16(1):100-2. PubMed ID: 22338554
[TBL] [Abstract][Full Text] [Related]
3. Voriconazole-induced QT interval prolongation and ventricular tachycardia: a non-concentration-dependent adverse effect.
Alkan Y; Haefeli WE; Burhenne J; Stein J; Yaniv I; Shalit I
Clin Infect Dis; 2004 Sep; 39(6):e49-52. PubMed ID: 15472801
[TBL] [Abstract][Full Text] [Related]
4. QT prolongation and Torsades de Pointes in patients previously treated with anthracyclines.
Arbel Y; Swartzon M; Justo D
Anticancer Drugs; 2007 Apr; 18(4):493-8. PubMed ID: 17351403
[TBL] [Abstract][Full Text] [Related]
5. Voriconazole: new preparation. Invasive aspergillosis: benefits to be confirmed.
Prescrire Int; 2004 Feb; 13(69):13-6. PubMed ID: 15055210
[TBL] [Abstract][Full Text] [Related]
6. Torsades de pointes upon fluconazole administration in a patient with acute myeloblastic leukemia.
Tatetsu H; Asou N; Nakamura M; Hanaoka N; Matsuno F; Horikawa K; Mitsuya H
Am J Hematol; 2006 May; 81(5):366-9. PubMed ID: 16628725
[TBL] [Abstract][Full Text] [Related]
7. A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML).
Vehreschild JJ; Böhme A; Buchheidt D; Arenz D; Harnischmacher U; Heussel CP; Ullmann AJ; Mousset S; Hummel M; Frommolt P; Wassmer G; Drzisga I; Cornely OA
J Infect; 2007 Nov; 55(5):445-9. PubMed ID: 17822770
[TBL] [Abstract][Full Text] [Related]
8. [Experience with voriconazole in invasive aspergillosis].
Thiel E; Schwartz S
Mycoses; 2003; 46 Suppl 2():3-7. PubMed ID: 15055137
[TBL] [Abstract][Full Text] [Related]
9. Inherited long QT syndrome revealed by antifungals drug-drug interaction.
Eiden C; Peyrière H; Tichit R; Cociglio M; Amedro P; Blayac JP; Margueritte G; Hillaire-Buys D
J Clin Pharm Ther; 2007 Jun; 32(3):321-4. PubMed ID: 17489884
[TBL] [Abstract][Full Text] [Related]
10. Breakthrough zygomycosis during voriconazole treatment for invasive aspergillosis.
Kobayashi K; Kami M; Murashige N; Kishi Y; Fujisaki G; Mitamura T
Haematologica; 2004 Nov; 89(11):ECR42. PubMed ID: 15533847
[No Abstract] [Full Text] [Related]
11. Voriconazole-induced QT interval prolongation and torsades de pointes.
Aypar E; Kendirli T; Tutar E; Çiftçi E; Ince E; Ileri T; Atalay S
Pediatr Int; 2011 Oct; 53(5):761-763. PubMed ID: 21955009
[No Abstract] [Full Text] [Related]
12. Effect of arsenic trioxide on QT interval in patients with advanced malignancies.
Barbey JT; Pezzullo JC; Soignet SL
J Clin Oncol; 2003 Oct; 21(19):3609-15. PubMed ID: 14512391
[TBL] [Abstract][Full Text] [Related]
13. Voriconazole-induced pancreatitis in a patient of acute myeloid leukemia and invasive aspergillosis.
Philip A; Sivaprakasam P; Sagar TG; Ganesan P
J Pediatr Hematol Oncol; 2012 Jul; 34(5):406. PubMed ID: 22713708
[No Abstract] [Full Text] [Related]
14. Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis.
Sambatakou H; Dupont B; Lode H; Denning DW
Am J Med; 2006 Jun; 119(6):527.e17-24. PubMed ID: 16750972
[TBL] [Abstract][Full Text] [Related]
15. Effect of combined fluoroquinolone and azole use on QT prolongation in hematology patients.
Zeuli JD; Wilson JW; Estes LL
Antimicrob Agents Chemother; 2013 Mar; 57(3):1121-7. PubMed ID: 23229485
[TBL] [Abstract][Full Text] [Related]
16. Long QTc interval and torsade de pointes caused by fluconazole.
Pham CP; de Feiter PW; van der Kuy PH; van Mook WN
Ann Pharmacother; 2006; 40(7-8):1456-61. PubMed ID: 16849620
[TBL] [Abstract][Full Text] [Related]
17. Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis.
Howard A; Hoffman J; Sheth A
Ann Pharmacother; 2008 Dec; 42(12):1859-64. PubMed ID: 19017830
[TBL] [Abstract][Full Text] [Related]
18. Primary cutaneous aspergillosis in an immunocompetent patient: successful treatment with oral voriconazole.
Craiglow B; Hinds G; Antaya R; Girardi M
Pediatr Dermatol; 2009; 26(4):493-5. PubMed ID: 19689543
[TBL] [Abstract][Full Text] [Related]
19. Successful management of invasive aspergillosis with voriconazole and amphoteracin B therapy in a patient with acute mycloid leukemia (AML-M2).
Manzoor NF; Azim S; Fadoo Z
J Pak Med Assoc; 2010 Nov; 60(11):977-9. PubMed ID: 21375212
[TBL] [Abstract][Full Text] [Related]
20. Outcome and medical costs of patients with invasive aspergillosis and acute myelogenous leukemia-myelodysplastic syndrome treated with intensive chemotherapy: an observational study.
Slobbe L; Polinder S; Doorduijn JK; Lugtenburg PJ; el Barzouhi A; Steyerberg EW; Rijnders BJ
Clin Infect Dis; 2008 Dec; 47(12):1507-12. PubMed ID: 18990068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
